Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies

PALO ALTO, Calif., December 16, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare…Original Article